Yabuuchi E, Ohyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol. 1971. https://doi.org/10.1111/j.1348-0421.1971.tb00607.x.

Article  PubMed  Google Scholar 

Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C, Massip C, et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013. https://doi.org/10.1128/AEM.02293-13.

Article  PubMed  PubMed Central  Google Scholar 

Hugon E, Marchandin H, Poirée M, Fosse T, Sirvent N. Achromobacter bacteraemia outbreak in a paediatric onco-haematology department related to strain with high surviving ability in contaminated disinfectant atomizers. J Hosp Infect. 2015. https://doi.org/10.1016/j.jhin.2014.07.012.

Article  PubMed  Google Scholar 

Spilker T, Vandamme P, LiPuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013. https://doi.org/10.1016/j.jcf.2012.10.002.

Article  PubMed  Google Scholar 

Spilker T, Vandamme P, LiPuma JJ. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol. 2012. https://doi.org/10.1128/JCM.00814-12.

Article  PubMed  PubMed Central  Google Scholar 

Sorlin P, Brivet E, Jean-Pierre V, Aujoulat F, Besse A, Dupont C, et al. Prevalence and variability of siderophore production in the Achromobacter genus. Microbiol Spectr. 2024. https://doi.org/10.1128/spectrum.02953-23.

Article  PubMed  PubMed Central  Google Scholar 

Amoureux L, Bador J, Bounoua Zouak F, Chapuis A, De Curraize C, Neuwirth C. Distribution of the species of Achromobacter in a French cystic fibrosis centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates. J Cyst Fibros. 2016. https://doi.org/10.1016/j.jcf.2015.12.009.

Article  PubMed  Google Scholar 

Garrigos T, Dollat M, Magallon A, Folletet A, Bador J, Abid M, et al. Distribution of Achromobacter species in 12 French cystic fibrosis centers in 2020 by a retrospective MALDI-TOF MS spectrum analysis analysis. J Clin Microbiol. 2022. https://doi.org/10.1128/jcm.02422-21.

Article  PubMed  PubMed Central  Google Scholar 

Amoureux L, Bador J, Verrier T, Mjahed H, De Curraize C, Neuwirth C. Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples. Epidemiol Infect. 2016. https://doi.org/10.1017/S0950268816001564.

Article  PubMed  Google Scholar 

Barrado L, Brañas P, Orellana MÁ, Martínez MT, García G, Otero JR, et al. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid. Spain J Clin Microbiol. 2013. https://doi.org/10.1128/JCM.00494-13.

Article  PubMed  Google Scholar 

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters Version 13.1; 2023. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf. Accessed 10 Mar 2024.

Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int J Antimicrob Agents. 2010. https://doi.org/10.1016/j.ijantimicag.2009.08.015.

Article  PubMed  Google Scholar 

Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012. https://doi.org/10.1111/j.1469-0691.2011.03570.x.

Article  PubMed  Google Scholar 

Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Achromobacter infections and treatment options. Antimicrob Agents Chemother. 2020. https://doi.org/10.1128/AAC.01025-20.

Article  PubMed  PubMed Central  Google Scholar 

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019. https://doi.org/10.1007/s40265-019-1055-2.

Article  PubMed  Google Scholar 

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016. https://doi.org/10.1093/jac/dkv402.

Article  PubMed  Google Scholar 

Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017. https://doi.org/10.1007/s10096-017-3063-z.

Article  PubMed  Google Scholar 

Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016. https://doi.org/10.1128/AAC.01405-16.

Article  PubMed  PubMed Central  Google Scholar 

Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.01454-17.

Article  PubMed  PubMed Central  Google Scholar 

Esposito S, Pisi G, Fainardi V, Principi N. What is the role of Achromobacter species in patients with cystic fibrosis? Front Biosci. 2021. https://doi.org/10.52586/5054.

Article  Google Scholar 

Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. Does cefiderocol have a potential role in cystic fibrosis pulmonary exacerbation management? Microb Drug Resist. 2021. https://doi.org/10.1089/mdr.2020.0602.

Article  PubMed  Google Scholar 

Gainey AB, Burch A, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020. https://doi.org/10.1002/ppul.24945.

Article  PubMed  Google Scholar 

Belcher R, Zobell JT. Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: meropenem-vaborbactam and cefiderocol. Pediatr Pulmonol. 2021. https://doi.org/10.1002/ppul.25552.

Article  PubMed  Google Scholar 

Bodro M, Hernández-Meneses M, Ambrosioni J, Linares L, Moreno A, Sandoval E, et al. Salvage treatment with cefiderocol regimens in two intravascular foreign body infections by MDR Gram-negative pathogens, involving non-removable devices. Infect Dis Ther. 2021. https://doi.org/10.1007/s40121-020-00385-4.

Article  PubMed  PubMed Central  Google Scholar 

McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother. 2021. https://doi.org/10.1128/AAC.02171-20.

Article  PubMed  PubMed Central  Google Scholar 

Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciaa1847.

Article  PubMed  PubMed Central  Google Scholar 

La Bella G, Salvato F, Minafra GA, Bottalico IF, Rollo T, Barbera L, et al. Successful treatment of aortic endocarditis by Achromobacter xylosoxidans with cefiderocol combination therapy in a non-Hodgkin lymphoma patient: case report and literature review. Antibiotics. 2022. https://doi.org/10.3390/antibiotics11121686.

Article  PubMed  PubMed Central  Google Scholar 

Fendian ÁM, Albanell-Fernández M, Tuset M, Pitart C, Castro P, Soy D, et al. Real-life data on the effectiveness and safety of cefiderocol in severely infected patients: a case series. Infect Dis Ther. 2023. https://doi.org/10.1007/s40121-023-00776-3.

Article  PubMed  PubMed Central  Google Scholar 

Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care. 2023. https://doi.org/10.1186/s13613-023-01146-5.

Article  PubMed  PubMed Central  Google Scholar